Former Valeant Executive Denied Reconsideration in Securities Fraud Suit
The former head of Valeant Pharmaceuticals International Inc.' s dermatology division was unable to convince a court to end a class action lawsuit accusing the generic drugmaker and its executives of engaging in a massive scheme to fraudulently inflate the company's stock prices.
from Biotech News
0 Comments